Der er indberettet maligniteter (inklusive kutant T- celle lymfomer (CTCL) og hudkræft) under den kliniske udvikling og i tiden efter markedsføringen i forbindelse med brugen af topisk pimecrolimus.
Case reports of malignancies (including cutaneous T-Cell lymphoma (CTCL) and skin cancer) have been received during the clinical development and post-marketing experience in association with the use of topical pimecrolimus.